Sustainable Development Goals (SDGs)

In September 2015, a new era of global development began when the United Nations (UN) officially launched its Sustainable Development Goals (SDGs) to transform our world and “leave no one behind” by 2030.

The UN has called for broad-based support of the SDGs, including active involvement by the private sector. To make a significant and sustainable impact, the public and private sectors, as well as civil society stakeholders, are seeking to align activities and work together. Pfizer is committed to helping facilitate industry engagement and aligning our corporate objectives to accelerate impact for healthy individuals and patients across the globe.

At Pfizer, our purpose – to bring innovative therapies to patients that significantly improve their lives – forms the basis of our commitment to all 17 of the SDGs, particularly Goal 3 – delivering Good Health and Well-Being. Every day, we use our knowledge, expertise and resources to find new ways to positively impact public health, which in turn advances other global development objectives. We call this approach to global health Entrepreneurship for Good, and we are committed to using it to help achieve the SDGs.

Throughout this report, you’ll see the SDG icons to highlight the work we are doing across Pfizer to meet these achievements by 2030.

To learn more about all 17 SDGs, please visit the UN website.
Partnering to Achieve the UN SDGs

Supporting Goal 3: Good Health and Well-Being
The Sustainable Development Goals that We Are Tackling

While Pfizer is committed to helping achieve all 17 SDGs, the ones listed below are closely aligned to our mission as an R&D-based biopharmaceutical company:

**Goal 3**  
**Good Health and Well-Being**  
We promote holistic solutions to meet the health needs of the underserved while investing in the well-being of the global community.

**Goal 5**  
**Gender Equality**  
We seek to empower and mobilize women around the world through partnerships aimed at ensuring access to quality health care, including newborn immunizations and family planning services.

**Goal 6**  
**Clean Water and Sanitation**  
Through public-private partnerships like the International Trachoma Initiative, as well as efforts to responsibly manage our water consumption and disposal, we aim to advance public health by improving water supply, sanitation and hygiene.

**Goal 9**  
**Industry, Innovation and Infrastructure**  
We catalyze scientific innovation through cutting-edge research initiatives and unique, results-driven partnerships in order to deliver novel medicines, vaccines and know-how to individuals around the world.

**Goal 11**  
**Sustainable Cities and Communities**  
We promote healthy behavior for people of all ages in urban environments through programs to reduce pollution, promote age-friendly policies and improve health services for those most in need.

**Goal 12**  
**Responsible Consumption and Production**  
Throughout the lifecycle of our products, we are working toward reducing our carbon footprint and increasing energy efficiency, decreasing dependence on limited resources and reducing waste.

**Goal 17**  
**Partnerships for the Goals**  
Through innovative partnerships, including collaborations with non-governmental organizations (NGOs), governments, foundations, social entrepreneurs and colleagues, we seek to fuel creative approaches that accelerate progress and improve health care.
Our Priority, Goal 3: Good Health and Well-Being

For Pfizer, SDG 3: Good Health and Well-Being, is inextricably linked to our belief that every individual deserves to lead a long, healthy and productive life. Good health is fundamental to advancing all of the 17 SDGs, each of which directly benefits from or contributes to advances in public health.

Pfizer is exploring ways to build commercially sustainable, socially responsible business models that address areas of significant public health need in developed, middle-income and developing countries. And by partnering with socially responsible entrepreneurs, we are working collectively to advance progress toward health targets identified by the UN as critical to achieving SDG 3.

Progress Made toward Transforming Good Health and Well-being by 2030

<table>
<thead>
<tr>
<th>Target by 2030</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target 3.1</strong> By 2030, reduce the global maternal mortality ratio to less than 70 per 100,000 live births.</td>
<td>We support a program with the 2020 MicroClinic in Kenya to implement evidenced-based interventions that decrease maternal and neonatal mortality and improve access to antenatal and postnatal services, including access to a skilled birth attendant.</td>
</tr>
<tr>
<td><strong>Target 3.2</strong> By 2030, end preventable deaths of newborns and children under five years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-five mortality to at least as low as 25 per 1,000 live births.</td>
<td>Since 2014, the Pfizer Foundation has supported a program with Save the Children to improve access to childhood immunizations and family planning services for women in Malawi. The initiative provides vital newborn services like immunization, along with access to information and services in family planning for post-partum women. Through this program we have reached over 290,000 children with health and nutrition services while working with the local Ministry of Health to address barriers to integrating family planning services.</td>
</tr>
<tr>
<td><strong>Target 3.3</strong> By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases.</td>
<td>Pfizer has entered into collaborations to expand scientific research with the Medicines for Malaria Venture (MMV), the Drugs for Neglected Diseases initiative (DNDi), and the World Health Organization Special Programme for Research and Training in Tropical Diseases (WHO-TDR). These organizations have access to our library of chemical entities and are screening them for compounds that can serve as catalysts to develop new drugs that target malaria and other tropical diseases.</td>
</tr>
<tr>
<td><strong>Target 3.5</strong> Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol.</td>
<td>We are working to help combat the development of abuse-deterrent opioids and we are committed to the manufacturing of naloxone, a prescription medicine indicated for complete or partial reversal of acute opioid over dosage. Pfizer has launched the Pfizer Naloxone Access Program, a multifaceted initiative that addresses the prevention, treatment and effective response to the issue of opioid overdose. As part of the program, Pfizer will provide, free of charge, up to 1 million doses of naloxone between 2017 and 2020 to Direct Relief, a not-for-profit agency independent of Pfizer and licensed to distribute medicines to charitable and community clinics in all 50 states and the District of Columbia. Pfizer is also providing $1 million in charitable grants across five states to fund initiatives focused on increasing public awareness of the risks of opioid addiction. Learn more about <a href="#">The Pfizer Naloxone Access Program</a>.</td>
</tr>
</tbody>
</table>
Target by 2030

**Target 3.7** By 2030, ensure universal access to sexual and reproductive health care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programs.

**Progress**

Since 2014, the Pfizer Foundation* has awarded $12 million as part of its Women and Children’s Health portfolio to address barriers to accessing health care, including:

- Working with PACE (the Program for Accessible Health Communication and Education), the affiliate of Population Services International (PSI) in Uganda, this program is specifically aimed at young women and adolescent girls. It has been designed to gain a better understanding of the health market, to overcome barriers to access and to respond to young people’s sexual and reproductive needs in a meaningful and engaging way. The program also increases access to family planning information and products, as well as other reproductive health services, including HIV testing and treatment for sexually transmitted infections.

- A project with the U.S. Fund for UNICEF to expand use of mobile health platforms to improve immunization delivery and health outcomes for children in their first 1,000 days of life in Uganda.

- An initiative with CARE to improve the family planning counseling and clinical skills of health care providers and integrate these services into routine immunization delivery, while reducing misconceptions about family planning in under-served communities in Benin.

A collaboration with the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation to help broaden access to Pfizer’s long-acting injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries. Learn more about this collaboration.

**Target 3a** Strengthen the implementation of the WHO Framework Convention on Tobacco Control in all countries, as appropriate.

The China Tobacco Control Partnership, with funding support from Pfizer, is providing grants and expert support to five cities that aim to lessen the use of tobacco, so that smoking is no longer the norm.

- Each grantee city will work toward adopting comprehensive smoke-free policies, educate the public on harms of tobacco use and secondhand smoke, and deliver targeted tobacco-control programs that decrease smoking, reduce exposure to secondhand smoke and encourage smokers to quit.

- Via city-wide public legislation, indoor smoke-free policy implementation, training workshops, tobacco control-themed health events, large-scale World No Tobacco Day events, cessation competitions and other activities, the partnership has resulted in:
  - Protection of 64.6 million people from secondhand smoke exposure where Smoke-Free Public Places policies were adopted
  - Delivery of health education to 2.12 million people via 622 health education events
  - Adoption of 214 smoke-free policies in businesses.

---

* The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
Communicating Our Progress toward the Sustainable Development Goals

To underscore the importance of industry engagement with these goals, Pfizer sought to raise public awareness about the SDGs this year. We started close to home, wrapping our New York City global headquarters building – located two blocks from UN Headquarters – with key messages and icons in partnership with the UN Foundation. Through this effort, diplomats, tourists and native New Yorkers alike were introduced to the SDGs and Pfizer’s commitment to help achieve them.

We then took the SDGs on the road. We developed an interactive booth that shared information on the goals and amplified Pfizer’s support at key conferences, including: Devex World (Washington, D.C.), Mashable Social Good Summit (New York, N.Y.) and Cleveland Clinic Medical Innovation Summit (Cleveland, Ohio). We intend to continue our awareness raising activities outside the United States in 2017.